CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,734 calls trading, 1.3x expected, and implied vol increasing almost 4 points ...

“I am thrilled to join such an innovative company at the forefront of gene editing,” said Briggs Morrison, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR ...

WASHINGTON — Robert F. Kennedy Jr. is distancing himself from his anti-vaccine work as he seeks to become the leader of the ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...